Physician profile
John P Tanner
NPI 1699983411
$1,233.46
in general payments reported to CMS, 2019-2025
14 companies · $157 in 2025
The $157 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $326 · 2021: $72.28 · 2023: $208 · 2024: $159 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $530.49 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $252.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $109.76 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $65.73 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $54.25 | 2019-2020 | |
| Amarin Pharma, INC. | $45.36 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.31 | 2019-2021 | |
| Boston Scientific Corporation | $29.87 | 2025 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $26.06 | 2019-2020 | |
| Eisai INC. | $22.98 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.97 | 2020 | |
| Astellas Pharma US INC | $13.89 | 2020 | |
| Gilead Sciences, INC. | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.